CNBX leader in cancer related cannabinoid-based medicine

CNBX Cannabics Pharmaceuticals has an agreement with Purisys, a leading Active Pharmaceutical Iingredient manufacturer, to use its API in Phase I/II (a) clinical studies that it is planning to launch in 2022.

So this year will be quite bullish for CNBX

Cannabics Pharmaceuticals is a U.S. public company and a global leader in the development of cancer related cannabinoid-based medicine. It engages in the discovery, development and commercialization of novel cannabinoid-based products and innovative technologies for the treatment of cancer.

52 Week Range 0.08 - 0.60
Market Cap 15.163M

Short term upside: $0.20
After they begin the Phase I/II (a) clinical studies, the stock can reach once again its 52 week highs.


The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.